News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

Commentary|Slideshows|January 30, 2025

Clinical Pearls: Discussing ADHD at Real Psychiatry

Author(s)Erin Crown, MHS, PA-C, Psych-CAQ, Michael Asbach, DMSc, PA-C, Psych-CAQ, Mark Jankelow, MSN, PMHNP-BC

Check out these insights from clinicians at Real Psychiatry!

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

visoot/Adobe Stock

What's New in Psychiatric Treatment? Highlights From the 2026 Southern California Psychiatry Conference

ByJessica Walters

July 30th 2026

LaTerase/Adobe Stock

FDA Approves Centanafadine for ADHD in Children, Adolescents, and Adults

ByJessica Walters

July 24th 2026

maslakhatul/Adobe Stock

Centanafadine's Route to FDA Review: A Clinical Path of the ADHD Medication

ByJessica Walters

July 23rd 2026

What Clinicians Might Miss in ADHD: Sleep Disorders, Comorbidities, and a Link to Depression

What Clinicians Might Miss in ADHD: Sleep Disorders, Comorbidities, and a Link to Depression

ByAnn Childress, MD

July 11th 2026

Expanding ADHD Pharmacology: Pipeline Highlights With Ann Childress, MD

ByAnn Childress, MD

July 10th 2026

Latest CME

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Trending on Psychiatric Times

Preventing Alzheimer Disease After Brain Injury: Targeting TNF With XPro1595

Can Psychiatry Lead in Building Brain Capital? Why Mental Health Matters for Policy, Economy, and Society

PET Imaging Confirms Lower Muscarinic M1 Receptor Availability in Schizophrenia

Categories vs Dimensions: Wave or Particle?

What's New in Psychiatric Treatment? Highlights From the 2026 Southern California Psychiatry Conference